The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet on July 23–24, 2026 to review whether several peptides — including BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and Emideltide (also referred to by the FDA as delta sleep-inducing peptide, or DSIP) — should be added to the FDA’s bulk drug compounding list. This is a developing regulatory process, not a finalized rule, and this article summarizes what is actually confirmed as of publication, what remains undecided, and what it does and doesn’t mean for research buyers.
This is a news and industry-context article. It does not offer legal advice, and nothing here changes how Alpha Tides PNW sells any product: every compound on this site remains strictly Research Use Only, for laboratory research by qualified professionals.
What the PCAC Meeting Is Actually Reviewing
The Pharmacy Compounding Advisory Committee advises the FDA on which substances qualify for inclusion on the agency’s bulk drug compounding lists — the mechanism that allows licensed 503A and 503B compounding pharmacies to prepare a substance for a patient under a valid prescription when no FDA-approved commercial product meets a specific clinical need. The July 23–24, 2026 session is set to review seven peptides for possible addition to that list: BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and Emideltide (DSIP). Per the FDA’s published meeting agenda, day one (July 23) covers BPC-157, KPV, TB-500, and MOTS-C; day two (July 24) covers Emideltide (DSIP), Semax, and Epitalon.
It’s worth being precise about what this process is: the FDA has historically declined similar requests for some of these substances, citing insufficient safety and efficacy data. A PCAC recommendation to add a substance is not the same as final FDA action, and even final action would apply only to the compounding-pharmacy pathway — not to any other category of sale.
Source: FDA, “Pharmacy Compounding Advisory Committee; Notice of Meeting,” Docket No. FDA-2025-N-6895, Federal Register, published April 16, 2026 (accessed July 20, 2026).
How This Differs From the Research Peptide (RUO) Market
It’s easy to conflate this review with the broader research-peptide industry, but the two are governed by entirely separate frameworks:
| Pathway | What it covers |
|---|---|
| Compounding pharmacies (503A/503B) | Prepare a specific substance for a specific patient under a valid prescription and physician oversight, if that substance is on an approved bulk compounding list. This is the pathway the PCAC review concerns. |
| Research Use Only (RUO) sales | Products sold explicitly for laboratory and analytical research by qualified professionals, not for human or animal use, and not distributed under a prescription or clinical framework at all. |
A peptide being added to (or kept off) the compounding list has no bearing on how it can be labeled, marketed, or sold under the RUO framework. See the companion article on what RUO actually means, linked below, for a fuller explanation of that distinction.
Context: The March 2026 Peptide Sciences Shutdown
This regulatory review doesn’t exist in isolation. In March 2026, Peptide Sciences — historically one of the largest peptide vendors in the US — shut down following Department of Justice enforcement activity related to grey-market peptide distribution. Public reporting on the case consistently frames the issue as marketing conduct — using RUO labeling while marketing product for human use — rather than the legality of research-use sales itself. Combined with the PCAC review, 2026 has been an active year for regulatory and enforcement attention on the peptide industry generally, which is exactly why sourcing practices and vendor transparency matter more than they did even a year ago.
What Research Buyers Should Actually Watch For
Rather than treating this as a signal that any particular compound is “becoming legal” or “getting banned,” researchers evaluating vendors should track:
- Whether the PCAC’s July 23–24 recommendations result in any compounds actually being added to the FDA bulk compounding list, and when.
- Whether continued DOJ/FTC enforcement activity targets specific marketing practices rather than the RUO category broadly.
- Whether a given vendor’s own marketing and documentation practices hold up to the same scrutiny described in the RUO explainer linked below — this is the part actually within a buyer’s control.
Summary: Key Takeaways for Researchers
The essential points for research buyers tracking this review are:
- Not a decision yet: the PCAC meeting on July 23–24, 2026 is a recommendation-forming session, not final FDA action.
- Separate framework: the 503A/503B compounding-pharmacy pathway under review here has no legal bearing on RUO research sales.
- Seven substances, two days: BPC-157, KPV, TB-500, and MOTS-C are discussed July 23; Emideltide (DSIP), Semax, and Epitalon are discussed July 24.
- Watch enforcement, not labels: recent DOJ/FTC activity has targeted marketing conduct, not the RUO category itself — vendor documentation and labeling practices are what buyers can actually evaluate.
Related Research Guides
- Understanding RUO: What “Research Use Only” Actually Means in 2026
- Red Flags When Sourcing Research Peptides
- What Is BPC-157? A Research Guide
- How to Read a Peptide Certificate of Analysis
- Certificates of Analysis
This article reflects public reporting and official FDA docket information available as of July 20, 2026, and summarizes a developing regulatory process; details may change as the PCAC meeting and any subsequent FDA action proceed. It does not constitute legal advice. All compounds referenced are sold strictly for laboratory research use only, not for human or animal use.
The compound(s) discussed in this article are available with a Certificate of Analysis on the Alpha Tides shop.
Frequently Asked Questions
No. As of publication, the Pharmacy Compounding Advisory Committee is scheduled to review these substances on July 23–24, 2026. A committee review and recommendation is not the same as final FDA action, and the FDA has declined similar requests for some of these substances in the past.
BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and Emideltide — which the FDA's docket identifies as delta sleep-inducing peptide (DSIP) — are the seven peptides scheduled for PCAC review at the July 2026 meeting.
No. The compounding-pharmacy pathway (503A/503B, prescription-based) is legally separate from RUO research sales. This review does not change how RUO products are labeled, marketed, or sold.
They are separate events on a shared timeline. The March 2026 shutdown involved DOJ enforcement over marketing practices; the PCAC review is a compounding-list evaluation process. Both reflect increased regulatory attention on the peptide industry in 2026, but neither directly caused the other.
Alpha Tides PNW sells BPC-157, KPV (as a component of the KLOW blend), and DSIP — which the FDA's docket lists as Emideltide — strictly for laboratory research, RUO, regardless of the outcome of the compounding-pharmacy review process described here.
Research Compounds
Research Use Only — Not for Human or Animal Consumption. Content is provided for informational and educational purposes and does not constitute medical advice.
Continue Your Research
Browse the full catalog of COA-verified research compounds.
Shop All Compounds →